Outcomes of type 2 diabetes management: one center experience 2015–2023
Authors:
Chlup Rudolf 1,2,3; Zálešáková Hana 3; Gottwaldová Jiřina 3; Trefil Michal 3; Zapletalová Jana 4; Kaňa Richard 3; Hanáčková Lada 3; Bretšnajdrová Milena 1; Falt Přemysl 1; Polzerová Zdenka 3
Authors‘ workplace:
II. interní klinika – gastroenterologická a geriatrická, Fakultní nemocnice Olomouc
1; Ústav fyziologie, Lékařská fakulta Univerzity Palackého v Olomouci
2; Diabetologická ambulance Moravský Beroun, Odborný léčebný ústav Paseka
3; Ústav lékařské biofyziky, Lékařská fakulta Univerzity Palackého v Olomouci
4
Published in:
Geriatrie a Gerontologie 2024, 13, č. 4: 167-183
Category:
Original Article
doi:
https://doi.org/10.61568/geri/50-6431/20241226/139520
Overview
The purpose of this chapter was (1) to identify the frequency of employing different kinds of medication (beta-stimulators, metformin, gliflozins, incretins and/or insulins, pioglitazone, statins, fibrates), (2) to assess global metabolic effectiveness of this medication in a walk-in diabetes center, and, (3) to estimate frequency of HbA1c measurements in people admitted to hospital. Methods: in 200 people with T2D (age 24–95 y, 105 men, 95 women) HbA1c, BM, BMI, blood pressure, lipoproteins HDL, LDL, TAG, eGFR, proteinuria were assessed. Individual observation periods took in the range of 0.5–8.8 years. Student’s t-test, Wilcoxon signed-rank test with Bonferroni correction and Spearman analysis were used to assess changes between the first and the last visit. P <0.05 was considered as significant. In conclusion, reduction of HbA1c from start values of 52.6 (31.5–173.0) to 46.6 (31.5–116.6) mmol/mol along with reduction of BMI from 26.7 (16.0–45.3) to 25.4 (15.4–42.2) kg/m2 (P <0.0001) and correlation of delta HbA1c with delta BMI (r = 0.209, p = 0.003) confirmed global metabolic effectiveness of medication used in the walk-in diabetes center where the HbA1c was estimated 2–3 times per year in each subject whereas in hospital wards mostly once in up to 15% of admitted T2D patients.
Keywords:
HbA1c, lipoproteins, estimated glomerular filtration rate, albuminuria, blood pressure, body mass, metformin, insulin, incretins, dapagliflozin, statins, quality of life, education, gluco-meters, continuous glucose monitoring, insulin pumps
Sources
Originální práce: Chlup R, Zálešáková H, Gottwaldová J, Trefil M, Zapletalová J, Kaňa R, Hanáčková L, Bretšnajdrová M, Falt P, Polzerová Z. Outcomes of type 2 diabetes management: one center experience 2015–2023 (Internet). Type 2 diabetes in 2024 – from early suspicion to effective management. IntechOpen; 2024. Available from: http://dx.doi.org/10.5772/intechopen.1005206
©2024 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: http://dx.doi.org/10.5772/intechopen.1005206
Aktualizovaný překlad originálu: Noemi Nováková
|
Korespondenční adresa: prof. MUDr. Rudolf Chlup, CSc. II. interní klinika – gastroenterologická a geriatrická Fakultní nemocnice Olomouc Zdravotníků 248/7 779 00 Olomouc e-mail: Rudolf.Chlup@fnol.cz |
1. Chlup R, Kaňa R, Hanáčková L, et al. Pathophysiologic approach to type 2 diabetes management: One centre experience 1980-2020. Available from: https://www.researchgate.net/publication/349698872_Pathophysiologic_Approach_to_Type_2_Diabetes_Management_One_Centre_Experience_1980-2020.
2. Friedecký B, Kratochvíla J, Springer D, et al.; for the Czech Society of Clinical Biochemistry and for the Czech Diabetes Society CLS JEP. Diabetes mellitus – laboratorní diagnostika a sledování stavu pacientů. Diabetes mellitus – laboratory diagnostics and observation of patients’ condition. Klin Biochem Metab 2019; 27(48): 32–47.
3. Hanas R, John G; on behalf of the International HbA1c Consensus Committee 2010. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010; 33: 1903–1904.
4. Chlup R, Doubravová B, Bartek J, et al. Effective assessment of diabetes control using personal glucometers (Contourlink, Bayer, Germany; Calla, Wellion, Austria; Linus, Agamatrix, USA). Disease Markers 2013; 35(6): 895–905.
5. Aronson R, Reznik Y, Conget I, et al.; for the OpT2mise Study Group. Sustained efficacy of inzulin pump therapy compared with multiple injections in type 2 diabetes: 12-month data from the OpT2mise randomised trial. Diabetes Obesity and Metabolism 2016.
6. Chlup R, Runzis S, Castaneda J, et al. Complex assessment of metabolic effectiveness of inzulin pump therapy in patients with type 2 diabetes beyond HbA1c reduction. Diabetes Technology and Therapeutics 2018; 20(2):153–159.
7. Šoupal J, Petruželková L, Grunberger G, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by inzulin delivery method: 3 years of follow-up from the COMISAIR study. Diabetes Care 2020; 43: 37–43.
8. Chlup R, Zapletalová J, Zálešáková H, et al. Vliv léčby inzulinem Fiasp na glykemii, HbA1c a tělesnou hmotnost u osob s diabetem 1. a 2. typu: studie z reálné praxe. (Benefits of inzulin Fiasp for persons with diabetes type 1 and diabetes type 2. Czech.) Diab Obez 2019; 19(38): 90–97.
9. Heise T, Hövelmann U, Brøndsted, L et al. Faster-acting inzulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than inzulin aspart. Diabetes Obes Metab 2015; 17(7): 682–688.
10. Bowering K, Case C, Harvey J, et al. Faster aspart versus inzulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: Onset 2 trial. Diabetes Care 2017; 40(7): 951–957.
11. Rodbard H, Tripathy D, Vidrio Velazquez M, et al. Adding fast-acting inzulin aspart to basal inzulin significantly improved glycaemic control in patients with type 2 diabetes: a randomised, 18-week, open-label, phase 3 trial
(Onset 3). Diabetes Obes Metab 2017; 19(10): 1389–1396.
12. Olšovský J. Klinické zkušenosti s inzulínem faster aspart – Fiasp. (Clinical experience with faster inzulin aspart – FIASP. Czech.). Kazuistiky v diabetologii (Case reports in Diabetology) 2018; 16(2): 25–26.
13. Chlup R, Zálešáková H, Zapletalo-
vá J, et al. Ersatz der langfristigen kontinuierlichen subkutanen Inzulininfusion (CSII) bei Typ 2 Diabetikern durch Inzulin Degludec und Liraglutide (IDegLira) einmal täglich hat meistens eine verbesserte Stofwechsellage zur Folge. (Replacement of the CSII in persons with T2D by IDegLira once daily mostly results in improved metabolic control. German.) Diabetologie und Stoffwechsel 2021; 16(1): 14.
14. Chlup R, Zapletalová J, Cheng TH, et al. Effects of incretins in people with type 2 diabetes on CSII. Diabetes 2017; 66(Suppl 1): A623 2387-PUB (Abstract).
15. Chlup R, Zálešáková H, Zapleta-
lová J, et al. Semaglutide: Dosiserhöhung auf 1 mg/Woche hat breitere metabolische Auswirkungen zur Folge. (Semaglutide: increasing the dose to 1 mg/week results in improved balance. German.) Diabetologie und Stoffwechsel 2022; 17(1): 26 (Abstract).
16. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65: 1925–1966.
17. Lasserson DS, Glasziou P, Perera R, et al. Optimal inzulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologica 2009; 52: 1990–2000.
18. Kumar Jha P, Shukla H, Makwana A, et al. Pharmacotherapy of type 2 diabetes mellitus (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen; 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002309.
19. Bahn Kawa L. Management of type 2 diabetes mellitus (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen; 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002478.
20. Nováková N, Nezval M, Molnáro-
vá V. Pathophysiology-oriented treatment of type 2 diabetes: 10 case reports (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen; 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002857.
21. Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia 2023; 66: 1780–1795.
22. Tschöp M, Nogueiras R, Ahrén B (2023) Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. https://doi.org/10.1007/s00125-023-05929-0.
23. Drucker DJ, Holst JJ (2023) The expanding incretin universe: from basic biology to clinical translation. Diabetologia. https://doi.org/10.1007/s00125-023-05906-7.
24. Mathieu C, Ahmadzai I (2023) Incretins beyond type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-023-05980-x.
25. Solini A, Tricò D, Del Prato S (2023) Incretins and cardiovascular disease: to the heart of type 2 diabetes? Diabetologia. https://doi.org/10.1007/s00125-023-05973-w.
26. Goldney J, Sargeant JA, Davies MJ (2023) Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia. https://doi.org/10.1007/s00125-023-05988-3.
27. Andreasen CR, Andersen A, Vilsbøll T (2023) The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease. Diabetologia. https://doi.org/10.1007/s00125-023-05966-9.
28. Karagiannis T, Bekiari E, Tsapas A (2023) Socioeconomic aspects of incretin-based therapy. Diabeto-
logia. https://doi.org/10.1007/s00125-023-05962-z.
29. Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2023). https:
//doi.org/10.1007/s00125-023-06053-9 .
30. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995–2008.
31. Wiviott SD, Raz I, Bonaca MP, et al.; for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357.
32. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; for the DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436–1446.
33. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387(12): 1089–1098.
34. Vícha M, Skala T, Jelínek L, et al. Pharmacotherapy of diabetes mellitus in patients with heart failure – a nation-wide analysis of contemporary treatment. Bio-
med Pap Med Fac Univ Palacky Olomouc 2023; 167(2): 177–184.
35. Kohnert KD, Augstein P, Heinke P, et al. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 77: 420–426.
36. Nuha A, El Sayed, Grazia Aleppo, et al.; on behalf of the American Diabetes Association, 6. Glycemic Targets: Standards of Care in Diabetes—2023. Diabetes Care 2023; 46 (Suppl 1): S97–S110.
37. Peterson K, Chlup R, Zapletalová J, et al. Influence of oral antidiabetic drugs on hyperglycemic response to foods in persons with type 2 diabetes mellitus as assessed by continuous glucose monitoring system: A pilot study. J Diabetes Sci Technol 2010; 4(4): 983–992.
38. Poljaková I, Elšíková E, Chlup R, et al. Glucose sensing module – is it time to integrate in into real-time perioperative monitoring? An observational pilot study with subcutaneous sensors. Biomed Pap 2013; 157(4): 346–357.
39. Gajdova J, Karasek D, Goldmannova D, et al. Pulse wave analysis and diabetes mellitus. A systematic review. Biomedical Papers 2017; 161(3): 223–233.
40. Kuss O, Opitz ME, Brandstetter LV, et al. How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials. Diabetologia 2023; 66: 1622–1632.
41. Amsal Elfa Gustanar L, Miftah Fajari N. Screening and testing for prediabetes and type 2 diabetes in asymptomatic adults (Internet). Type 2 diabetes: from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002298.
42. Gudat U. Fuelling life and managing surplus: revisiting type 2 diabetes (Internet). Type 2 diabetes: from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002613.
43. Kumwenda MJ. Dyslipoproteinaemia: important concern in type 2 diabetes (Internet). Type 2 diabetes: from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002514.
44. Mitrea A, Mihaela Vladu I, Magdalena Rosu M, et al. Paradigm of insulin resistance, type 2 diabetes, obesity, fatty liver and atherosclerosis in metabolic syndrome (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002510.
45. Zaid Aljulifi M. Complementary and alternative medicine in type 2 diabetes (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002422.
46. Grover-Páez F, Maya Gómez A, Hernández Suárez A, et al. From a glycocentric approach to prevention of multi-organ damage in type 2 diabetes. (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002363.
47. Gică N, Huluță I. Gestational diabetes mellitus (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen; 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002793.
48. Weber P, Weberová D, Meluzinova H. Diabetes in old age – particularities and specifics (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002479.
49. Waataja J, Ikramuddin S, Gal D, et al. Perspective chapter: Exploring the potential of vagus nerve neuromodulation as a personalized and enhanced therapeutic experience for type 2 diabetics (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen 2023. Available from: http://dx.doi.org/10.5772/intechopen.1002713.
50. Dhanapalaratnam R, Issar T, Lee ATK, et al. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia 2024. Available from: https://doi.org/10.1007/s00125-023-06072-6.
51. da Cruz Renó L, Araújo Cortines Laxe Renó A. The angiosome concept and endovascular techniques for limb salvage (Internet). Type 2 diabetes – from diagnosis to effective management (working title). IntechOpen 2024. Available from: http://dx.doi.org/10.5772/intechopen.1003988.
52. Molnárová V. Vliv semaglutidu na klinické a laboratorní ukazatele v léčbě diabetu 2. typu. (Impact of semaglutide on clinical and laboratory parameters in treatment of T2D. Czech.) Supplementum of Students’ Scientific Conference, Mai 2023, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, p. 98.
53. Chlup R, Zálešáková H, Nováková N, et al. Pathophysiologic approach in type 2 diabetes – single center study 2015–2023. Supplementum, 18th annual research meeting 22nd March, 2024, Topolčianky, Slovakia: s. 14–21.
54. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
55. Jörgens V. Die Geschichte der Diabetes-forschung vom Opium zum Inzulin. 1st ed. Mainz: Verlag Kirchheim+Co GmBH; 2022: 303.
56. Rothberg A, Lean M, Laferrère B. Remission of type 2 diabetes: always more questions, but enough answers for action. Diabetologia 2024. Available from: https://doi.org/10.1007/s00125-023-06069-1.
57. Fovenyi J. Eighty six years duration of type 1 diabetes mellitus. J Clin Diabetes 2019; 3: e104.
58. Fövényi J, Greschik I, Jermendy AL, et al. Clinical observations in patients with type 1 diabetes of over 50 years duration in one practice in Hungary. International Journal of Clinical Science and Medical Research 2023; 3(01): 11–17.
59. Korec R. Experimental and spontaneous diabetes mellitus in the rat and mouse. Edition Center of University PJ Šafárik, Košice, ČSFR, Košice, 199, p. 1–246.
60. Bruns W, Fiedler H, Altman B, et al. Inzulintherapie bei Typ 2 Diabetes Pathophysiologisch begründete Therapie mit Inzulin unter besonderer Berücksichtigung der Inzulinresistenz und des Inkre-
tineffektes. (Inzulin treatment in T2D Pathophysiology-based inzulin treatment with particular consideration of inzulin resistance and incretins. German.) 2. Auflage; UNIMED Verlag, AG, Bremen, 2010.
61. Bruns W, Preusse GHW. Opus 99… und andere Fragmente aus der Geschichte der deutsch-russischen Familie Bruns. Versuch einer lite-
rarischen Annäherung. (Opus 99 … and other particles from the real past of a german-russian family. Attempt of an artistic construction. German.) 1. Auflage 2014, Berlin, Trafo Verlagsgruppe Dr Wolfgang Weist, trafo Literaturverlag Reihe Autobiographien Band 47.
62. Berger M, Jörgens V, Mühlhauser I. Rationale for the use of inzulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 1999; 22(Suppl 3): C71–C75.
Doplňky k českému překladu:
CZ1. Kvapil M. Přínos a rizika nových antidiabetik pro léčbu diabetiků vyššího věku. Geri a Gero 2024; 13(2): 81–85.
CZ2. Chlup R, Kaňa R, Polcerová J, et al. Možnosti léčby diabetu při oslabení kognitivních funkcí. „Syndrom trosečníka (cast away)“. Kazuistiky v diabetologii 2019; 17(2): 35–40.
CZ3. Peterson K, Zapletalová J, Kudlová P, et al. Benefits of three-month continuous glucose monitoring for persons with diabetes using inzulin pumps and sensors. Biomed Papers 2009; 153(1): 47–52.
CZ4. Kvapil M, Nováková M, Matvejeva D, et al. Nové parametry pro hodnocení metabolismu glukózy u seniorních pacientů s diabetes mellitus. Geri a Gero 2024; 13(2): 77–80.
CZ5. Liarakos AL, Lim JZM, Leelarathna L, et al. The use of technology in type 2 diabetes and prediabetes: a narrative review. Diabetologia 2024. Available from: https://doi.org/10.1007/s00125-024-06203-7.
CZ6. Khunti K, Zaccardi F, Amod A, et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia (2024). Available from: https://doi.org/10.1007/s00125-024-06254-w.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2024 Issue 4
Most read in this issue
- Urinary tract infections in old age
- Outcomes of type 2 diabetes management: one center experience 2015–2023
- Overview of falls in patients at the Geriatric Ward of Olomouc University Hospital in relation to pharmacotherapy and other risk factors
- Electrostimulation in the treatment of dysphagia